Daily Respiratory Research Analysis
Analyzed 220 papers and selected 3 impactful papers.
Summary
Three clinically impactful studies advanced respiratory care: a meta-analysis showed lung ultrasound has high diagnostic accuracy for acute respiratory failure at the bedside; a prospective self-controlled bronchoscopy study demonstrated that post-brushing BALF significantly improves Xpert MTB/RIF sensitivity for pulmonary tuberculosis; and a very large real-world cohort linked positive airway pressure adherence in obese OSA patients to fewer ER visits, hospitalizations, and lower costs in a dose–response fashion.
Research Themes
- Point-of-care imaging for acute respiratory failure
- Procedural optimization to enhance microbiologic TB yield
- Real-world outcomes of adherence in sleep-disordered breathing
Selected Articles
1. Lung Ultrasound for Diagnosis of Acute Respiratory Failure in Critically Ill Patients: A Systematic Review and Meta-Analysis.
Across 20 studies (n=3083 units), lung ultrasound demonstrated pooled sensitivity 0.89 and specificity 0.94 for identifying thoracic causes of acute respiratory failure, with LR+ 16.2, LR− 0.11 and AUC 0.97. Despite substantial heterogeneity, findings support lung ultrasound as a rapid bedside adjunct, while performance may be attenuated by limited acoustic windows and high PEEP.
Impact: Provides rigorous, pooled diagnostic accuracy for bedside lung ultrasound in ARF, informing protocols where transport imaging is risky or infeasible. Quantified likelihood ratios enable evidence-based pretest–posttest decision-making.
Clinical Implications: Incorporate lung ultrasound earlier in ARF evaluation to triage causes (e.g., edema, consolidation, pneumothorax) and reduce delays from transport imaging; ensure operator training and consider patient factors (obesity, ventilation settings) that may limit accuracy.
Key Findings
- Pooled sensitivity 0.89 and specificity 0.94 for thoracic causes of ARF across 20 studies (n=3083 units).
- Diagnostic likelihood ratios: LR+ 16.2 and LR− 0.11; SROC AUC 0.97 indicating excellent overall performance.
- Substantial heterogeneity; performance may be attenuated by limited acoustic windows (e.g., obesity) and high PEEP altering artifact patterns.
Methodological Strengths
- Comprehensive PRISMA-aligned search across multiple databases with dual independent screening and QUADAS-2 bias assessment.
- Bivariate random-effects modeling with likelihood ratios, DOR, Fagan nomograms, and GRADE appraisal.
Limitations
- High between-study heterogeneity and variable operator expertise and protocols.
- Potential performance modifiers (e.g., mechanical ventilation settings, body habitus) not uniformly reported.
Future Directions: Standardize lung ultrasound acquisition/interpretation, stratify by ventilation and body habitus, and evaluate impact on time-to-diagnosis and patient-centered outcomes in pragmatic trials.
BACKGROUND: Lung ultrasound is increasingly used as a bedside imaging modality in critically ill patients with acute respiratory failure (ARF), but its overall diagnostic performance across diverse settings remains uncertain. We conducted a diagnostic test accuracy meta-analysis to evaluate the accuracy of lung ultrasound in identifying the thoracic cause of ARF in critically ill patients. METHODS: We systematically searched MEDLINE, Embase, Web of Science, Scopus from inception to November 2025. Two reviewers independently performed study selection, data extraction, and QUADAS-2 quality assessment. Pooled sensitivity, specificity, and summary receiver operating characteristic (SROC) curves were estimated using a bivariate random-effects model; likelihood ratios, diagnostic odds ratio (DOR), Fagan nomogram, and Deek's funnel plot were derived. RESULTS: Twenty studies (3083 units; 1227 reference-positive, 1856 reference-negative) were included. Pooled sensitivity and specificity of lung ultrasound for thoracic cause of ARF were 0.89 (95% CI: 0.83-0.94) and 0.94 (95% CI:
2. The diagnostic yield of brushing versus non-brushing bronchoalveolar lavage fluid for Xpert MTB/RIF in patients with suspected tuberculosis: a prospective self-controlled study.
In 124 suspected TB patients (110 confirmed), Xpert MTB/RIF on post-brushing BALF achieved higher sensitivity than pre-brushing (93.6% vs 87.3%; P=0.014), with a 5.6% discordance between pairs. Gains were most pronounced in tree-in-bud CT patterns (92.0% vs 76.0%; P=0.025), while AFB smear and culture did not improve with brushing.
Impact: A simple procedural change during bronchoscopy (lesion brushing before BALF) significantly increases Xpert MTB/RIF sensitivity, enabling earlier, more reliable diagnosis of smear-negative PTB.
Clinical Implications: Prioritize post-brushing BALF for Xpert MTB/RIF during bronchoscopic workup of suspected PTB, especially with tree-in-bud CT findings; this may reduce diagnostic delays without added culture yield.
Key Findings
- Among 124 suspected cases (110 active TB), Xpert MTB/RIF had the highest sensitivity (93.6%).
- Post-brushing BALF increased Xpert sensitivity vs pre-brushing (93.6% vs 87.3%; P=0.014) with 5.6% discordance between paired samples.
- AFB smear and MGIT960 culture sensitivity did not improve after brushing; gains were greatest in tree-in-bud CT subgroup (92.0% vs 76.0%; P=0.025).
Methodological Strengths
- Prospective self-controlled paired-sample design minimizing inter-patient variability.
- Head-to-head evaluation of Xpert, AFB smear, and culture with subgroup analyses by CT phenotype and lavage segment.
Limitations
- Single-center study with moderate sample size; external validity needs confirmation.
- Clinical diagnosis used as reference standard may introduce verification bias.
Future Directions: Validate brushing-enhanced BALF workflows across diverse settings, quantify added yield vs procedure time/risks, and assess impact on time-to-treatment and transmission.
BACKGROUND: Bronchoalveolar lavage fluid (BALF) Xpert Mycobacterium tuberculosis and rifampicin resistance (Xpert MTB/RIF) is increasingly used as an important diagnostic method for sputum smear-negative pulmonary tuberculosis (PTB) in many countries. However, no studies have investigated whether collecting BALF with or without brushing from the lesion site affects the diagnostic yield of Xpert MTB/RIF for PTB. This study aims to evaluate the impact of Xpert MTB/RIF testing on BALF collected with and without brushing on the diagnostic yield for PTB. METHODS: In a self-controlled study design, BALF samples collected before and after brushing were obtained from 124 suspected PTB patients from Chongqing University Fuling Hospital between September 2020 and September 2023. All specimens were subjected to MGIT960 liquid culture, acid-fast bacillus (AFB) smear, and Xpert MTB/RIF testing. Using clinical diagnostic results as the reference standard, the sensitivity and specificity of AFB smear, MGIT960 culture, and Xpert MTB/RIF assays for MTB detection were compared between pre- and post-brushing BALF. Subgroup analyses stratified by chest CT features and lavage lung segments were conducted. RESULTS: Of the 124 suspected cases, 110 (88.7%) were confirmed as active tuberculosis. The diagnostic yield differed substantially among methods, with Xpert MTB/RIF demonstrating the highest sensitivity by detecting 103 cases (93.6%). Notably, a 5.6% discordance rate was observed between paired pre- and post-brushing samples, contributing to the significantly higher sensitivity of post-brushing Xpert MTB/RIF testing compared to pre-brushing testing (93.6% vs. 87.3%, P = 0.014). In contrast, the sensitivity of BALF AFB smear and mycobacterial culture showed no significant improvement after brushing (P > 0.05. Furthermore, subgroup analysis revealed that the increase in sensitivity was particularly pronounced in patients with a tree-in-bud sign on chest CT (92.0% vs. 76.0%, P = 0.025). CONCLUSIONS: Xpert MTB/RIF testing of post-brushing BALF enhances diagnostic sensitivity for PTB, particularly in patients with tree-in-bud CT findings. Prioritizing post-brushing specimens is recommended to improve early diagnosis rates, addressing diagnostic delays in challenging cases. This approach optimizes TB diagnostic workflows for timely clinical management.
3. Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity.
In 173,691 obese OSA patients with linked device data, PAP adherence was associated (post-IPTW) with fewer ER visits (0.55 vs 0.69), hospitalizations (0.10 vs 0.14), and lower total costs ($11,332 vs $11,927) at 1 year, with benefits persisting at 2 years. Intermediate adherence showed outcomes between adherent and nonadherent groups, indicating a dose–response.
Impact: Demonstrates population-level, dose–response economic and utilization benefits of PAP adherence in a high-burden phenotype (OSA with obesity), supporting investment in adherence programs.
Clinical Implications: Implement structured adherence interventions (education, telemonitoring, behavioral support) and payer policies that incentivize sustained PAP use to reduce ER visits, hospitalizations, and costs.
Key Findings
- Among 173,691 obese OSA patients, 35.2% were adherent, 39.1% intermediate, 25.7% nonadherent.
- After IPTW, adherent vs nonadherent at 1 year: fewer ER visits (0.55 vs 0.69) and hospitalizations (0.10 vs 0.14), both P<0.001.
- Lower total healthcare costs in adherent vs nonadherent ($11,332 vs $11,927; P<0.001); effects persisted at 2 years; intermediate adherence showed dose–response.
Methodological Strengths
- Very large, real-world cohort linking claims with cloud-connected PAP usage data.
- Robust adjustment using inverse probability of treatment weighting and multi-year follow-up.
Limitations
- Observational design with potential residual confounding and device–data capture biases.
- Generalizability may vary by healthcare system and adherence definitions.
Future Directions: Test scalable adherence-enhancing interventions in pragmatic trials and model payer-level cost savings; explore subgroups (e.g., severe OSA, cardiometabolic risk).
OBJECTIVE: Obstructive sleep apnea (OSA) and obesity are highly prevalent comorbid conditions associated with major societal and healthcare burden. Positive airway pressure (PAP) therapy is the first-line treatment for OSA. This study evaluated the association between PAP adherence and healthcare resource utilization (HCRU) and costs in patients with OSA and comorbid obesity. METHODS: This retrospective cohort study utilized de-identified claims data linked with cloud-connected PAP usage to analyze adults with obesity (ICD-10 code of obesity or morbid obesity or indicating BMI ≥ 30 kg/m RESULTS: Among 173,691 patients, 35.2% were adherent, 39.1% intermediately adherent, and 25.7% nonadherent. After applying inverse probability of treatment weighting (IPTW), in year 1 post-index, adherent patients had significantly fewer ER visits and hospitalizations (0.55 ± 1.77 and 0.10 ± 0.44) compared to nonadherent patients (0.69 ± 1.78 and 0.14 ± 0.56; P < 0.001), and significantly lower total healthcare costs (11,332 ± 21,160 vs 11,927 ± 20,212; P < 0.001). Similar findings were observed after 2 years of therapy with adherent patients having lower HCRU and costs than nonadherent patients. Patients with intermediate adherence had outcomes between those of adherent and nonadherent groups, suggesting a dose-dependent effect. CONCLUSIONS: Greater adherence to PAP therapy is associated with significantly lower HCRU and costs in patients with OSA and obesity, highlighting the importance of implementing strategies to improve long term PAP adherence, potentially reducing economic and clinical burden.